慢性阻塞性肺疾病患者血清腺苷酸环化酶蛋白-1水平及其临床意义

Level and clinical implication of serum CAP-1 in patients with chronic obstructive pulmonary disease

摘要:

目的  研究慢性阻塞性肺疾病（COPD）患者腺苷酸环化酶蛋白-1（CAP1）水平及其临床意义。方法  选取COPD急性加重期患者30例（急性期组），稳定期患者30例（稳定期组），健康体检者30例（对照组），抽取静脉血2 ml，采用酶联免疫法测定CAP1浓度；所有入选患者行肺功能检查。结果  急性期组血清CAP1浓度低于稳定期组（P =0.001），稳定期组低于对照组（P =0.001）；Pearson相关分析结果显示，急性期组和稳定期组血清CAP1浓度与第一秒用力呼气量占预计值的百分比（Predicted FEV1%）呈正相关（r =0.809，P =0.002）；急性期组和稳定期组血清CAP1浓度与第一秒用力呼气容积占用力肺活量的百分比（FEV1/FVC%）呈正相关（r =0.840，P =0.001）。结论  血清CAP1可能是COPD的保护因素，血清CAP1对判断病情严重程度有一定价值。

Abstract:

Objective To investigate the level and clinical implication of serum adenylyl cyclase-associated protein-1 (CAP-1) and its relationship with respiratory function in patients with chronic obstructive pulmonary disease (COPD). Methods The serum 1evel of CAP-1 was measured by ELISA in 30 cases of acute exacerbations of COPD (AECOPD) and 30 patients with stable COPD, 30 cases of healthy volunteers were included as controls. Lung ventilatory functions were measured in all patients and healthy controls. Results The concentration of serum CAP-1 was significantly lower in the stable COPD patients than in the volunteers (P = 0.001), and significantly lower in the patients with AECOPD than in the stable COPD patients (P = 0.001). Pearson correlation analysis showed that the level of serum CAP-1 was positively correlated with predicted FEV1% (r = 0.809, P = 0.002) and FEV1/FVC% (r = 0.840, P = 0.001). Conclusions Serum CAP-1 may be a protective factor of COPD, which has certain value in the evaluation of COPD.